This event is not part of the official Scientific Sessions Conference 2026 as planned by the American Heart Association Committee on Scientific Sessions Programming. Cardiac complications are the leading cause of mortality in Friedreich ataxia (FA); however, natural history data are lacking to comprehensively characterize the progression of FA cardiomyopathy (FA-CM). While hypertrophy is a common feature of FA-CM, this distinct cardiomyopathy often follows a different course than traditional HCM. Progressive cardiac remodeling and disease burden are not always fully reflected by conventional assessments, creating challenges for monitoring and prognostication. PAID ADVERTISEMENT Understanding Cardiac Disease Progression in Friedreich Ataxia Beyond Traditional HCM: Saturday, November 7, 1:45 – 2:30 PM CT Heart Theater 1 YOU ARE INVITED TO ATTEND A Heart Theater Sponsored by Lexeo Therapeutics, Inc. IN THIS SESSION WE WILL Describe the current understanding of the natural history and progression of cardiac involvement in FA. Discuss the importance of key biomarkers and quantitative imaging measures in assessing cardiac disease burden and progression. Apply evolving evidence to improve recognition, prognostication, and longitudinal management of patients with FA-CM. 1 2 3 MEET THE FACULTY Kimberly Y. Lin, MD Attending Pediatric Cardiologist, Cardiac Center Medical Director, Cardiomyopathy Program Associate Medical Director, Heart Function, Transplant & VAD Program Children's Hospital of Philadelphia Cordula M. Wolf, MD Pediatric Cardiologist Professor in Pediatrics, Technical University of Munich (TUM) Head of Cardiogenetics, Center for Rare Cardiovascular Diseases & Precision Medicine Department of Congenital Heart Defects & Pediatric Cardiology TUM University Hospital, German Heart Center Munich ©Lexeo Therapeutics, Inc. All Rights Reserved.
RkJQdWJsaXNoZXIy MjI2NjI=